Recent Company News

• 07:14 AM ET Feb 19, 2026
  

  NovaBridge Biosciences appoints Emmett T. Cunningham as Vice Chairman of the board ($3.29, 0.00)

• 04:10 PM ET Feb 17, 2026
  

  NovaBridge Biosciences doses first patient in global, randomized Phase 2 study of Givastomig combined with Immunochemotherapy in patients with 1L metastatic gastric cancer ($3.22, 0.00)

• 08:23 AM ET Jan 06, 2026
  

  StreetAccount Summary - US Pre-market trading

• 04:08 PM ET Jan 22, 2026
  

  NovaBridge Biosciences CEO Sean Fu intends to purchase up to $100K in ADS in open market transactions - 6-K ($3.89, 0.00)

• 04:09 PM ET Jan 16, 2026
  

  NovaBridge Biosciences Chair Fu Wei intends to repurchase up to $5M ADSs - 6-K ($3.73, 0.00)

• 09:20 AM ET Jan 06, 2026
  

  StreetAccount Summary - US Pre-market trading update